Diabetes Care Drugs Market Report 2026

The diabetes care drugs market size has grown strongly in recent years. It will grow from $73.48 billion in 2025 to $77.57 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to limited availability of advanced insulin formulations, growing awareness of diabetes management, rising healthcare infrastructure, dependence on oral antidiabetic drugs, increasing incidence of type 2 diabetes.

The diabetes care drugs market size is expected to see strong growth in the next few years. It will grow to $95.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel GLP-1 receptor agonists, adoption of SGLT-2 inhibitors, expansion of injectable and inhalable drug options, growth in home-based diabetes care, integration of digital health monitoring systems. Major trends in the forecast period include rising prevalence of diabetes worldwide, increased adoption of combination therapies, growth in personalized diabetes management, expansion of specialty pharmacies and hospital distribution channels, focus on extended-release and patient-friendly formulations.

The growing number of diabetic patients is anticipated to drive the expansion of the diabetes care drugs market in the coming years. Diabetic patients are individuals diagnosed with diabetes mellitus, a long-term metabolic disorder that affects the body’s ability to regulate blood glucose levels. The rise in the diabetic population is largely attributed to unhealthy dietary habits and sedentary lifestyles, which contribute to obesity and insulin resistance. Diabetes care drugs play a critical role in helping patients effectively manage blood sugar levels, making them essential for the treatment of both type 1 and type 2 diabetes. These medications help prevent complications by maintaining stable glucose levels, supporting overall health, and improving quality of life. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner were identified with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the rising number of diabetic patients is fueling the growth of the diabetes care drugs market.

Major companies operating in the diabetes care drugs market are concentrating on the development of advanced treatment options, such as fixed-ratio combination therapies, to improve glycemic control, boost patient adherence, and simplify treatment plans. Fixed-ratio combination therapies are medications that combine two complementary antidiabetic agents into a single injection, providing a more convenient and effective approach to diabetes management. For instance, in April 2024, Sanofi SA, a France-based pharmaceutical company, introduced Soliqua, a once-daily fixed-ratio combination of insulin glargine and lixisenatide designed for adults with type 2 diabetes and obesity. Soliqua integrates long-acting insulin glargine, which delivers consistent fasting glucose control, with lixisenatide, a GLP-1 receptor agonist. This formulation enhances glucose-dependent insulin secretion, reduces glucagon release, and slows gastric emptying to lower postprandial blood glucose levels, offering comprehensive daily glycemic regulation. The launch of Soliqua is intended to streamline diabetes management, enhance glycemic outcomes, and improve patient adherence by reducing the need for multiple injections and limiting side effects such as hypoglycemia and weight gain.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired certain anti-diabetes trademarks from Boehringer Ingelheim International GmbH for an undisclosed sum. Through this acquisition, Lupin obtained full trademark ownership of GIBTULIO, GIBTULIO MET, and AJADUO, allowing the company to independently market and integrate these oral antidiabetic medicines across India, thereby strengthening and expanding its diabetes care portfolio. Boehringer Ingelheim International GmbH is a Germany-based pharmaceutical company specializing in the development and manufacture of diabetes care drugs.

Major companies operating in the diabetes care drugs market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Wockhardt, Mitsubishi Tanabe Pharma, Gan & Lee Pharmaceuticals, Apotex.

North America was the largest region in the diabetes care drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes care drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the diabetes care drugs market by increasing costs for imported active pharmaceutical ingredients (APIs) and specialized delivery devices. Segments such as GLP-1 receptor agonists, SGLT-2 inhibitors, and insulin formulations are most impacted, particularly in regions like North America and Asia-Pacific where imports are significant. This has resulted in higher treatment costs and supply chain adjustments. However, tariffs also encourage local manufacturing, investment in domestic production capacities, and the development of cost-optimized formulations.

The diabetes care drugs market research report is one of a series of new reports that provides diabetes care drugs market statistics, including diabetes care drugs industry global market size, regional shares, competitors with a diabetes care drugs market share, detailed diabetes care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care drugs industry. This diabetes care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes care drugs are medications prescribed to control blood glucose levels in people with diabetes mellitus, including type 1 diabetes, type 2 diabetes, and gestational diabetes. These drugs act by increasing insulin production, improving insulin sensitivity, or decreasing glucose absorption in the body. Their primary objective is to maintain healthy blood sugar levels and prevent diabetes-related complications.

The main drug classes in diabetes care drugs include insulin, biguanides, sulfonylureas, dipeptidyl peptidase (DPP)-4 inhibitors, sodium-glucose co-transporter (SGLT)-2 inhibitors, glucagon-like peptide (GLP)-1 receptor agonists, thiazolidinediones, and alpha-glucosidase inhibitors. Insulin is a pharmaceutical form of the naturally occurring hormone that is administered by injection or inhalation to supplement inadequate insulin production or utilization in the body. These medications are available in multiple formulation types, including tablets, injections, solutions, gels, and extended-release formulations. They are administered through oral, injectable, and inhalable routes and are mainly used for the management of type 1 and type 2 diabetes. Distribution channels include hospital pharmacies and specialty pharmacies.

The diabetes care drugs market consists of sales of oral antidiabetic drugs, non-insulin injectable drugs, and combination drugs. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.